Cargando…

The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review

OBJECTIVE: To evaluate the effect of lifestyle changes on the severity of psoriasis and the quality of life in patients with psoriasis. METHODS: For this narrative review, PubMed, Embase and ClinicalTrials.gov were searched for lifestyle intervention studies with an intervention duration of at least...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Acht, Maartje R, van den Reek, Juul M P A, de Jong, Elke M G J, Seyger, Marieke M B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007593/ https://www.ncbi.nlm.nih.gov/pubmed/35433402 http://dx.doi.org/10.2147/PTT.S294189

Ejemplares similares

Real-world Methotrexate Use in a Prospective Cohort of Paediatric Patients with Plaque Psoriasis: Effectiveness, Adverse Events and Folic Acid Regimen
por: BRUINS, Finola M., et al.
Publicado: (2022)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)

Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
por: Mahé, E., et al.
Publicado: (2022)

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
por: ATALAY, Selma, et al.
Publicado: (2021)

The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy
por: van Muijen, Marloes E, et al.
Publicado: (2020)

Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study
por: van Hal, Tamara W, et al.
Publicado: (2021)

Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life
por: Purzycka-Bohdan, Dorota, et al.
Publicado: (2022)

Patients’ perspectives towards biologic dose reduction in psoriasis: a qualitative study
por: van der Schoot, L. S., et al.
Publicado: (2023)

Predicting treatment success with biologics in psoriasis
por: van den Reek, J.M.P.A.
Publicado: (2019)

Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort
por: VAN HAL, Tamara W., et al.
Publicado: (2022)

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2022)

Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
por: Busard, Celine, et al.
Publicado: (2017)

Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
por: Busard, Celine, et al.
Publicado: (2017)

Challenges in Noninvasive Skin Biomarker Measurements in Daily Practice: A Longitudinal Study on Skin Surface Protein Detection by the Transdermal Analysis Patch in Pediatric Psoriasis
por: Schaap, Mirjam J., et al.
Publicado: (2022)

Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial
por: Atalay, Selma, et al.
Publicado: (2017)

Perfusion measured by laser speckle contrast imaging as a predictor for expansion of psoriasis lesions
por: Schaap, Mirjam J., et al.
Publicado: (2021)

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review
por: Mulder, Michelle L. M., et al.
Publicado: (2021)

Development of a New Referral Tool to Identify Psoriasis Patients with Concomitant Psoriatic Arthritis: Results of the Prospective DAPPER Cohort
por: VAN HAL, Tamara W., et al.
Publicado: (2023)

Image‐based automated Psoriasis Area Severity Index scoring by Convolutional Neural Networks
por: Schaap, M.J., et al.
Publicado: (2021)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study
por: van der Schoot, Lara S., et al.
Publicado: (2021)

Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis
por: Langewouters, A. M. G., et al.
Publicado: (2007)

Quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study
por: van de Kerkhof, P.C.M., et al.
Publicado: (2019)

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
por: VAN MUIJEN, Marloes. E., et al.
Publicado: (2022)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
por: ATALAY, Selma, et al.
Publicado: (2020)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
por: van der Schoot, L.S., et al.
Publicado: (2023)

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
por: Seyger, M.M.B., et al.
Publicado: (2021)

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Data‐driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine
por: van der Schoot, L. S., et al.
Publicado: (2021)

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study
por: Thaçi, D., et al.
Publicado: (2019)

Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review
por: Michielsens, C. A. J., et al.
Publicado: (2021)

Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide
por: van Muijen, M. E., et al.
Publicado: (2021)

Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Blood-Based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients
por: Mulder, Michelle L. M., et al.
Publicado: (2021)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis
por: Gooderham, M., et al.
Publicado: (2022)

Global Risk of Bacterial Skin Infections and Herpesviridae Infections with Ustekinumab, Secukinumab, and Tumour Necrosis Factor-alpha Inhibitors: Spontaneous Reports of Adverse Drug Reactions from the World Health Organization Pharmacovigilance Center
por: DAVIDSON, Linda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_emmsji8psa4nhf0pdfd7dm3eqd